{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02563678",
            "orgStudyIdInfo": {
                "id": "1040229"
            },
            "organization": {
                "fullName": "Intermountain Health Care, Inc.",
                "class": "OTHER"
            },
            "briefTitle": "Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines",
            "officialTitle": "Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines: a Pilot Study",
            "acronym": "O2B",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "hyperbaric-oxygen-neutrophil-oxidative-burst-and-cytokines"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2015-04"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2015-09-15",
            "studyFirstSubmitQcDate": "2015-09-28",
            "studyFirstPostDateStruct": {
                "date": "2015-09-30",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2022-08-02",
            "lastUpdatePostDateStruct": {
                "date": "2022-08-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Lindell Weaver",
                "investigatorTitle": "Director, Hyperbaric Medicine",
                "investigatorAffiliation": "Intermountain Health Care, Inc."
            },
            "leadSponsor": {
                "name": "Intermountain Health Care, Inc.",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false
        },
        "descriptionModule": {
            "briefSummary": "In this small pilot study, participants (patients and healthy volunteers) will have blood drawn before and after the study intervention (hyperbaric chamber session or normal pressure oxygen breathing. This blood will be analyzed for neutrophil oxidative burst and cytokine analysis.",
            "detailedDescription": "The investigators are interested in studying the influence of hyperbaric oxygen on neutrophils (a kind of white blood cell) and cytokines (cell proteins). Hyperbaric oxygen can enhance the way the immune system works, but the investigators don't fully know how that happens. the investigators are doing this study to learn more about this question."
        },
        "conditionsModule": {
            "conditions": [
                "Infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Diabetics with active, chronic infection",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.",
                    "interventionNames": [
                        "Drug: Hyperbaric Oxygen"
                    ]
                },
                {
                    "label": "No diabetes or infection",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.",
                    "interventionNames": [
                        "Drug: Hyperbaric Oxygen"
                    ]
                },
                {
                    "label": "Critically ill patients with infection",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.",
                    "interventionNames": [
                        "Drug: Hyperbaric Oxygen"
                    ]
                },
                {
                    "label": "Carbon monoxide patients",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.",
                    "interventionNames": [
                        "Drug: Hyperbaric Oxygen"
                    ]
                },
                {
                    "label": "Glucose tolerance test",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.",
                    "interventionNames": [
                        "Drug: Hyperbaric Oxygen"
                    ]
                },
                {
                    "label": "Brain injury research subjects",
                    "type": "EXPERIMENTAL",
                    "description": "Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.",
                    "interventionNames": [
                        "Drug: Hyperbaric Oxygen"
                    ]
                },
                {
                    "label": "Hyperbaric chamber inside attendants",
                    "type": "EXPERIMENTAL",
                    "description": "Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).",
                    "interventionNames": [
                        "Other: Hyperbaric Air/Oxygen"
                    ]
                },
                {
                    "label": "Volunteers, hyperbaric oxygen",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.",
                    "interventionNames": [
                        "Drug: Hyperbaric Oxygen"
                    ]
                },
                {
                    "label": "Volunteers, normobaric pressure",
                    "type": "EXPERIMENTAL",
                    "description": "Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.",
                    "interventionNames": [
                        "Other: Normobaric oxygen"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Hyperbaric Oxygen",
                    "description": "Hyperbaric oxygen therapy",
                    "armGroupLabels": [
                        "Brain injury research subjects",
                        "Carbon monoxide patients",
                        "Critically ill patients with infection",
                        "Diabetics with active, chronic infection",
                        "Glucose tolerance test",
                        "No diabetes or infection",
                        "Volunteers, hyperbaric oxygen"
                    ],
                    "otherNames": [
                        "HBO, HBO2"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Hyperbaric Air/Oxygen",
                    "description": "Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber",
                    "armGroupLabels": [
                        "Hyperbaric chamber inside attendants"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Normobaric oxygen",
                    "description": "Breathing 100% oxygen at normal, atmospheric pressure",
                    "armGroupLabels": [
                        "Volunteers, normobaric pressure"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Oxidative Burst Assay",
                    "timeFrame": "Within 30 minutes after chamber session 1"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Cohort 1: Diabetic hyperbaric patients with active, chronic infection\n\nInclusion Criteria:\n\n* Adult patients (ages 18-65) presenting for an anticipated course of at least 4 hyperbaric oxygen sessions for chronic clinical indications (possible indications include diabetic lower extremity wounds or refractory osteomyelitis)\n* Diabetes mellitus\n* Current antibiotic use for active infection\n\nExclusion Criteria:\n\n* Prior treatment with hyperbaric oxygen within the last 30 days\n* Consistent vitamin C or vitamin E supplementation in the past year\n* Active tobacco use\n* Pregnancy\n\nCohort 2: Hyperbaric patients without diabetes or active infection\n\nInclusion Criteria:\n\n- Adult patients (ages 18-65) presenting for an anticipated course of at least 4 hyperbaric oxygen sessions for chronic clinical indications (possible indications include crush injury, acute peripheral arterial insufficiency, or radiation necrosis)\n\nExclusion Criteria:\n\n* Prior treatment with hyperbaric oxygen within the last 30 days\n* Consistent vitamin C or vitamin E supplementation in the past year\n* Active tobacco use\n* Pregnancy\n* Diabetes mellitus\n* Known or suspected viral or bacterial infection\n\nCohort 3: Critically ill hyperbaric patients with acute infection\n\nInclusion Criteria:\n\n- Adult patients (ages 18-65) admitted to the intensive care unit for acute, life-threatening infection where hyperbaric oxygen is clinically indicated for at least 4 sessions (possible indications include gas gangrene or necrotizing fasciitis)\n\nExclusion Criteria:\n\n* Prior treatment with hyperbaric oxygen within the last 30 days\n* Consistent vitamin C or vitamin E supplementation in the past year\n* Active tobacco use\n* Pregnancy\n\nCohort 4:\n\nCarbon monoxide-poisoned patients\n\nInclusion Criteria:\n\n- Adult patients (ages 18-65) presenting for hyperbaric oxygen for acute carbon monoxide poisoning (up to 3 sessions)\n\nExclusion Criteria:\n\n* Prior treatment with hyperbaric oxygen within the last 30 days\n* Consistent vitamin C or vitamin E supplementation in the past year\n* Active tobacco use\n* Pregnancy\n* Time interval between removal from carbon monoxide source and first hyperbaric oxygen session \\>12 hours\n\nCohort 5: Diabetic research subjects also undergoing glucose tolerance testing\n\nInclusion Criteria:\n\n* Co-enrollment in glucose tolerance testing study\n* Meet inclusion/exclusion profile for that study\n\nExclusion Criteria:\n\n* Prior treatment with hyperbaric oxygen within the last 30 days\n* Consistent vitamin C or vitamin E supplementation in the past year\n* Active tobacco use\n\nCohort 6: Brain injury research subjects\n\nInclusion Criteria:\n\n* Co-enrollment in brain injury study\n* Meet inclusion/exclusion profile for that study\n\nExclusion Criteria:\n\n* Known or suspected viral or bacterial infection\n* Consistent vitamin C or vitamin E supplementation in the past year\n* Active tobacco use\n\nCohort 7: Hyperbaric chamber inside attendants\n\nInclusion Criteria:\n\n- Employees (ages 18-65) medically cleared to work as hyperbaric chamber inside attendants, reporting for a regular duty day\n\nExclusion Criteria:\n\n* Known or suspected viral or bacterial infection\n* Consistent vitamin C or vitamin E supplementation in the past year\n* Active tobacco use\n* Prior work in the hyperbaric chamber in the last 72 hours\n\nCohort 8: Healthy volunteers to receive hyperbaric oxygen\n\nInclusion Criteria:\n\n* Healthy volunteers (ages 18-65)\n* Medical clearance for hyperbaric oxygen exposure\n\nExclusion criteria:\n\n* Hyperbaric oxygen exposure within the last 30 days\n* Active chronic medical condition\n* Use in the past 30 days of any over-the-counter or prescription medication or dietary supplement beyond a general multivitamin\n* Active tobacco use\n* History of significant health problems, including metabolic bone disease, skeletal muscle pathologies, cardiac or peripheral cardiovascular system abnormalities, clotting disorders, coronary artery disease, peripheral vascular disease, stroke, cancer, high cholesterol or triglycerides, high blood pressure, diabetes mellitus, or impaired liver/kidney function.\n* Morbidly obese (body mass index \\> 40 kg/m2)\n* Pregnancy\n* Known or suspected viral or bacterial infection\n\nCohort 9: Healthy volunteers to breathe 100% oxygen at atmospheric pressure\n\nInclusion Criteria:\n\n- Healthy volunteers (ages 18-65)\n\nExclusion criteria:\n\n* Hyperbaric oxygen exposure within the last 30 days\n* Active chronic medical condition\n* Use in the past 30 days of any over-the-counter or prescription medication or dietary supplement beyond a general multivitamin\n* Active tobacco use\n* History of significant health problems, including metabolic bone disease, skeletal muscle pathologies, cardiac or peripheral cardiovascular system abnormalities, clotting disorders, coronary artery disease, peripheral vascular disease, stroke, cancer, high cholesterol or triglycerides, high blood pressure, diabetes mellitus, or impaired liver/kidney function.\n* Morbidly obese (body mass index \\> 40 kg/m2)\n* Pregnancy\n* Known or suspected viral or bacterial infection",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lindell K Weaver, MD",
                    "role": "CONTACT",
                    "phone": "801-408-3623",
                    "email": "lindell.weaver@imail.org"
                },
                {
                    "name": "Susan Churchill, APRN-NP",
                    "role": "CONTACT",
                    "phone": "801-408-3623",
                    "email": "susan.churchill@imail.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Lindell K Weaver, MD",
                    "affiliation": "Intermountain Health Care, Inc.",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Intermountain Medical Center",
                    "status": "RECRUITING",
                    "city": "Murray",
                    "state": "Utah",
                    "zip": "84157",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Susan Churchill, APRN-NP",
                            "role": "CONTACT",
                            "phone": "801-408-3623",
                            "email": "susan.churchill@imail.org"
                        },
                        {
                            "name": "Lindell K. Weaver, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.66689,
                        "lon": -111.88799
                    }
                },
                {
                    "facility": "Intermountain Healthcare, LDS Hospital",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84143",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Susan Churchill, APRN-NP",
                            "role": "CONTACT",
                            "phone": "810-408-3623",
                            "email": "Susan.Churchill@imail.org"
                        },
                        {
                            "name": "Lindell K Weaver, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Susan Churchill, APRN-NP",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M5506",
                    "name": "Carbon Monoxide",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}